Trends of Prescription Drug Manufacturer Rebates in Commercial Health Insurance Plans, 2015-2019

Elizabeth Plummer; Mariana P Socal; Jeromie M Ballreich; Gerard F Anderson; Ge Bai

doi:10.1001/jamahealthforum.2022.0888

Trends of Prescription Drug Manufacturer Rebates in Commercial Health Insurance Plans, 2015-2019

JAMA Health Forum. 2022 May 6;3(5):e220888. doi: 10.1001/jamahealthforum.2022.0888. eCollection 2022 May.

Authors

Elizabeth Plummer^{1

2}, Mariana P Socal³, Jeromie M Ballreich³, Gerard F Anderson^{3

4}, Ge Bai^{3

5}

Affiliations

¹ Neeley School of Business, Texas Christian University, Fort Worth.
² TCU School of Medicine, Texas Christian University, Fort Worth.
³ Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
⁴ Johns Hopkins School of Medicine, Baltimore, Maryland.
⁵ Johns Hopkins Carey Business School, Baltimore, Maryland.

Abstract

This economic evaluation examines the magnitude and trend of prescription drug rebates in commercial markets from 2015 to 2019 and identifies insurance plan factors associated with rebates.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Insurance, Health
Prescription Drugs*
Prescriptions

Substances

Prescription Drugs